The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we performed a large …

The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …

Overtreatment with cisplatin-based chemotherapy is a major issue in the management of
muscle-invasive bladder cancer (MIBC), and currently none of the reported biomarkers for …

Background Genomic regions identified by genome-wide association studies (GWAS) for
bladder cancer risk provide new insights into etiology. Objective To identify new susceptibility …

Background The functional status of immune cells in the tumor microenvironment and tumor
characteristics may explain bacillus Calmette-Guérin (BCG) failure in high-risk non–muscle-…

Background An improved risk assessment of patients with bladder cancer (BC) is important
to optimize clinical management. Objective To identify whether immune cell subpopulations …

Background Field cancerization is characterized by areas of normal tissue affected by
mutated clones. Bladder field cancerization may explain the development and recurrence of …

Purpose: Most bladder cancers are early-stage tumors known as papillary non–muscle-invasive
bladder cancer (NMIBC). After resection, up to 70% of NMIBCs recur locally, and up to …

Objective Improvements to bladder cancer risk stratification guidelines are needed to better
tailor post-operative surveillance and adjuvant therapy to individual patients. We previously …

Background Current bulk transcriptomic classification systems for bladder cancer do not
consider the level of intratumor subtype heterogeneity. Objective To investigate the extent and …